Dolasynthen, Other, Publications Site-Specific Dolasynthen Antibody-Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles Across a Wide Range of Drug to Antibody Ratios
Immunosynthen, Other, Publications Discovery and Optimization of a STING Agonist Platform for Application in Antibody Drug Conjugates
Dolasynthen, Publications, XMT-1660 Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody-Drug Conjugate for the Treatment of Cancer
Other, Other, Publications UPGRADE-A: Phase 1 Expansion Trial of the NaPi2b-Directed Antibody Drug Conjugate Upifitamab Rilsodotin in Combination With Carboplatin in Patients With High-Grade Serous Ovarian Cancer
Other, Other, Publications Correlating Expression of NaPi2b and Folate Receptor Alpha (FRα) in High‑Grade Serous Ovarian Cancer (HGSOC)
Other, Other, Publications UP‑NEXT (GOG‑3049/ENGOT‑ov71‑NSGO‑CTU): A Study of Upifitamab Rilsodotin (UpRi), a NaPi2b‑directed Antibody‑Drug Conjugate in Platinum‑Sensitive Recurrent Ovarian Cancer
Dolasynthen, Publications, XMT-1660 XMT‑1660: A Phase 1b Trial of a B7‑H4–Targeting Antibody‑Drug Conjugate (ADC) in Breast, Endometrial, and Ovarian Cancers
Other, Other, Publications Advances in Ovarian Cancer Care and Unmet Treatment Needs for Patients with Platinum Resistance
Immunosynthen, Publications, XMT-2056 XMT-2056, a HER2-Directed STING Agonist Antibody-Drug Conjugate, Exhibits ADCC Function that Synergizes with STING Pathway Activation and Contributes to Anti-tumor Responses
